AKT1 and hepatocellular carcinoma: PD98059 has been demonstrated to inhibit human HCC [69], LY294002 has been shown to decrease the capacity of HCC cell migration and invasion of liver tumors [70], and rapamycin treatment has been shown to significantly delay hepatocarcinogenesis in AKT/Ras mice [71].